WMBC-TV talks to Dr. Howard Fillit about promising developments in Alzheimer's treatments at our 16th International Conference on Alzheimer's Drug Discovery.
This episode of "Faces of Philanthropy" focuses on mental wellness and features staff, supporters, and funded scientists from the ADDF.
08/04/2015Dr. Gary Gibson discusses his upcoming clinical trial with the Wall Street Journal's Tanya Rivero.
Of the 199 windows on the wavy walls of the Lou Ruvo Center for Brain Health in Las Vegas, no two are on the same plane. A specialized plaster coating on the walls ensures that the acoustics ring true amid this architectural free-for-all. The setting uncannily echoed the vibe at Opportunities and Challenges in Combination Therapy for Alzheimer’s Disease, an advisory panel meeting that took place at the Frank Gehry-designed building on May 28. Twenty-one clinicians, computational modelers, regulators, and leaders from foundations and pharma gathered to chart a path for using repurposed drugs in combination trials for Alzheimer’s. In 13 presentations and a two-hour discussion, they debated how drugs should be selected and whether combo trials were even ready for prime time. In the end, the panel concluded that combination therapy, in one form or another, may be needed to truly make a mark on AD. Leaders from the Alzheimer’s Association and the Alzheimer’s Drug Discovery Foundation (ADDF) agreed to request proposals for combination therapies on repurposed drugs, with details to come.
Biogen Inc.'s recent revelation of promising early data from an experimental Alzheimer's treatment is something of a breakthrough: it's the first time that we have seen positive human data about a new Alzheimer's drug that can both reduce the presence of amyloid plaques in the brain and improve cognitive function.
A new study from the University of Texas Medical Branch at Galveston has revealed that a single dose of an immunotherapy reverses memory problems in an animal model of Alzheimer’s disease. The article appears in the March 25 issue of the Journal of Neuroscience. \Researchers have been working for decades to map out how Alzheimer’s disease wields its devastating effects. Although it’s known that two molecules – tau and amyloid beta – are considered responsible for the disease’s progression, the relationship between these two proteins and resulting memory problems has remained unclear.
If the analysts are right, this Sunday Julianne Moore will win an Academy Award for her performance in "Still Alice." Moore is heartbreakingly brilliant in the film, starring as a middle-aged linguistics professor coming to the slow and painful realization that she has early-onset Alzheimer's. It's a powerful, important performance, bringing into focus a devastating disease that is all too often hidden from sight. But it's also an opportunity for Moore, who absorbed so many real stories in preparation for this all-consuming role, to do something more.
A patient of mine disappeared the other night. B. Smith, the well-known entertainment and lifestyle personality, had just come to my office for a consultation. In the year since her diagnosis of Alzheimer’s at a still-beautiful age 64, her family had clung to the words early stage, but after 90 minutes of geriatric assessment, it was clear to me that B.’s condition was considerably worse than anyone had thought. Despite the fact that her social personality appeared intact, her cognitive function was severely impaired. Her short-term memory was almost completely gone. She had no idea of the year or where she was, couldn’t draw a clock, couldn’t even subtract 2 from 10.
Group of British pensioners to be given Viagra in world first scientific experiment to see if it combats dementia. The world's first clinical trials in London will explore whether the Viagra-style drug could help prevent a common form of dementia by increasing blood flow to the brain. Scientists will be using the drug Tadalafil, which works by dilating blood vessels, in helping to prevent the onset of vascular dementia, the second most common form of dementia which accounts for 110,000 cases in the UK.
NPR announced the sad news on Monday, November 4th, that Tom Magliozzi, the co-host of the wildly popular radio show, "Car Talk", had died from complications from Alzheimer's disease. Magliozzi and his younger brother, Ray, known to listeners as Click and Clack, The Tappet Brothers, entertained their fans on NPR from 1987 until 2012, when they ended their Peabody Award-winning program. Magliozzi's family has requested that, in lieu of flowers, friends and listeners make a donation to the Alzheimer's Association or their favorite public radio station in his memory. In a singular twist of synchronicity, Magliozzi's death happened to coincide with the Alzheimer's Drug Discovery Foundation's Fifth Annual Fall Symposium & Luncheon "Hope on the Horizon", which was held at The Pierre Hotel on 5th Avenue onthe same day.